Zhuhai Rundu Pharmaceutical Co., Ltd. announced that its amlodipine besylate active pharmaceutical ingredient has recently received marketing approval from the National Medical Products Administration, with registration number Y20240001262. The API is used for the treatment of hypertension and angina pectoris. The company submitted its registration application in January 2025, received a supplementary study notice in November 2025, completed the supplementary study and submitted the materials in March 2026, and obtained approval in August 2026. The company stated that this approval will improve its product portfolio in the cardiovascular and cerebrovascular treatment field, enrich its product matrix, and help enhance market competitiveness, while also noting that future sales may be subject to uncertainty due to policy and market changes.
Zhuhai Rundu Pharmaceutical Co Ltd Class AIts amlodipine besylate API received marketing approval from the National Medical Products Administration, expanding its cardiovascular product portfolio.
